<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetol Metab Syndr</journal-id><journal-id journal-id-type="iso-abbrev">Diabetol Metab Syndr</journal-id><journal-title-group><journal-title>Diabetology &#x00026; Metabolic Syndrome</journal-title></journal-title-group><issn pub-type="epub">1758-5996</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24548643</article-id><article-id pub-id-type="pmc">4094276</article-id><article-id pub-id-type="publisher-id">1758-5996-6-24</article-id><article-id pub-id-type="doi">10.1186/1758-5996-6-24</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effect of moderate alcohol consumption on fetuin-A levels in men and women: post-hoc
analyses of three open-label randomized crossover trials</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Joosten</surname><given-names>Michel M</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>mmjoosten@gmail.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Schrieks</surname><given-names>Ilse C</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>ilse.schrieks@tno.nl</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Hendriks</surname><given-names>Henk FJ</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>henk.hendriks@tno.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>TNO (a Dutch acronym for Netherlands Organisation of Applied Scientific Research),
Zeist, the Netherlands</aff><aff id="I2"><label>2</label>Division of Human Nutrition, Wageningen University, Wageningen, the
Netherlands</aff><aff id="I3"><label>3</label>Department of Internal Medicine, University of Groningen, University Medical
Center Groningen, Groningen, the Netherlands</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>18</day><month>2</month><year>2014</year></pub-date><volume>6</volume><fpage>24</fpage><lpage>24</lpage><history><date date-type="received"><day>22</day><month>10</month><year>2013</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Joosten et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Joosten et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which
permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly credited. The Creative Commons Public Domain Dedication waiver
(<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data
made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.dmsjournal.com/content/6/1/24"/><abstract><sec><title>Background</title><p>Fetuin-A, a liver-derived glycoprotein that impairs insulin-signalling, has
emerged as a biomarker for diabetes risk. Although moderate alcohol consumption
has been inversely associated with fetuin-A, data from clinical trials are
lacking. Thus, we evaluated whether moderate alcohol consumption decreases
circulating levels of fetuin-A.</p></sec><sec><title>Methods</title><p>We analyzed data of three separate open-label, randomized, crossover trials: 1) 36
postmenopausal women consuming 250&#x000a0;ml white wine (25&#x000a0;g alcohol) or white
grape juice daily for 6&#x000a0;weeks, 2) 24 premenopausal women consuming
660&#x000a0;ml beer (26&#x000a0;g alcohol) or alcohol-free beer daily for 3&#x000a0;weeks,
and 3) 24 young men consuming 100&#x000a0;ml vodka (30&#x000a0;g alcohol) orange juice
or only orange juice daily for 4&#x000a0;weeks. After each treatment period fasting
blood samples were collected.</p></sec><sec><title>Results</title><p>Circulating fetuin-A concentrations decreased in men after vodka consumption
(Mean&#x02009;&#x000b1;&#x02009;SEM: 441&#x02009;&#x000b1;&#x02009;11 to
426&#x02009;&#x000b1;&#x02009;11&#x000a0;&#x003bc;g/ml, <italic>p</italic>&#x02009;=&#x02009;0.02), but not
in women after wine (448&#x02009;&#x000b1;&#x02009;17 to
437&#x02009;&#x000b1;&#x02009;17&#x000a0;&#x003bc;g/ml, <italic>p</italic>&#x02009;=&#x02009;0.16) or beer
consumption (498&#x02009;&#x000b1;&#x02009;15 to
492&#x02009;&#x000b1;&#x02009;15&#x000a0;&#x003bc;g/ml, <italic>p&#x02009;=</italic>&#x02009;0.48) compared
to levels after each corresponding alcohol-free treatment. Post-hoc power analyses
indicated that the statistical power to detect a similar effect as observed in men
was 30% among the postmenopausal women and 31% among the premenopausal women.</p></sec><sec><title>Conclusions</title><p>In these randomized crossover trials, moderate alcohol consumption decreased
fetuin-A in men but not in women. This sex-specific effect may be explained by the
relatively short intervention periods or the low statistical power in the trials
among women.</p></sec><sec><title>Trials registration</title><p>ClinicalTrials.gov ID no&#x02019;s: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT00285909">NCT00285909</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT00524550">NCT00524550</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT00918918l">NCT00918918</ext-link>.</p></sec></abstract><kwd-group><kwd>Alcohol consumption</kwd><kwd>Fetuin-A</kwd><kwd>Insulin sensitivity</kwd><kwd>Liver enzymes</kwd><kwd>Type 2 diabetes mellitus</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Fetuin-A (&#x003b1;-Heremans-Schmid glycoprotein) is an abundant hepatokine that impairs
insulin signalling by inhibiting tyrosine kinase activity [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Several prospective studies have reported positive associations between
circulating fetuin-A and type 2 diabetes risk and, concomitantly, observed inverse
relations between alcohol consumption and fetuin-A [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. More importantly, a recent case-control study suggested that fetuin-A may
partially explain the reduced risk of type 2 diabetes [<xref ref-type="bibr" rid="B6">6</xref>] that has consistently been observed with moderate alcohol consumption [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. However, the cross-sectional and observational nature of these
alcohol-fetuin-A associations may raise concern about potential confounding. Thus, to
comprehensively investigate the effect of moderate alcohol consumption on fetuin-A
levels, we performed post-hoc analyses of three randomized crossover interventions with
different alcohol-containing beverages in men and women.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>The rationale of the three trials was to study the effect of moderate alcohol
consumption on markers of insulin sensitivity and/or inflammation. Each trial is
registered at ClinicalTrials.gov: NCT00285909, NCT00524550, and NCT00918918. Independent
medical ethics committees approved the research protocols (The Medical Ethics Committee
of the University Medical Centre Utrecht; Utrecht, the Netherlands [NCT00285909] and
METOPP; Tilburg, the Netherlands [NCT00524550, and NCT00918918]) and all participants
gave written informed consent. Eligible subjects were apparently healthy, were habitual
alcohol consumers, refrained from smoking, and had no family history of alcoholism. The
design of each individual intervention has been described in more detail elsewhere [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. In short, the three studies were open-label, randomized, crossover
intervention trials and were all conducted at TNO (a Dutch acronym for Netherlands
Organisation of Applied Scientific Research) in Zeist, the Netherlands. The trials
consisted of 1) 36 postmenopausal women consuming 250&#x000a0;ml white wine (25&#x000a0;g
alcohol; Chardonnay; Jean d&#x02019;Alibert, Rieux, France) or white grape juice (Albert
Heijn, Zaandam, the Netherlands) daily for 6&#x000a0;weeks between March and June 2006, 2)
24 premenopausal women consuming 660&#x000a0;ml beer (26&#x000a0;g alcohol) or alcohol-free
beer daily (both Amstel, Amsterdam, the Netherlands) for 3&#x000a0;weeks between August and
November 2007, and 3) 24 young men consuming 100&#x000a0;ml vodka (30&#x000a0;g alcohol;
Smirnoff, Diageo, London, UK) and 200&#x000a0;ml orange juice (Appelsientje, Riedel, Ede,
The Netherlands) or only orange juice daily for 4&#x000a0;weeks between August and November
2009. Postmenopausal women had an absence of menses for at least two years.
Premenopausal women used phase I or II oral contraceptives. Allocation to treatment
order (alcohol-containing vs. alcohol-free period) was randomized according to age and
body mass index (BMI). After each treatment period, fasting blood samples were obtained.
Plasma samples were stored at &#x02212;80&#x000b0;C (beer and vodka trials) and serum samples
at &#x02212;20&#x000b0;C (wine trial) until analysis. Fetuin-A concentrations were determined
by a sandwich enzyme-linked immunosorbent assay (ELISA) (R&#x00026;D Systems, Minneapolis,
MN) with a mean intra-assay coefficient of variation of 6.8%.</p><p>Data were analyzed using SAS statistical software (version 8.2; SAS Institute, Cary, NC,
USA). Variables were compared between treatments with a mixed analysis of variation
(ANOVA) model that included terms for treatment, period and the interaction between
period and treatment (indicating possible carryover effects). Correlation coefficients
were computed according to Spearman rank order to assess associations between
intervention-induced changes in fetuin-A and other biochemical variables. Data are
presented as mean&#x02009;&#x000b1;&#x02009;standard error of the mean (SEM). All tests were
two-sided. Statistical significance was defined as <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec><sec sec-type="results"><title>Results</title><p>All subjects completed both arms of their intervention. No notable adverse effects were
reported. Age and BMI were 56.5&#x02009;&#x000b1;&#x02009;4.2 y and
25.4&#x02009;&#x000b1;&#x02009;3.3&#x000a0;kg/m<sup>2</sup> in postmenopausal women,
23.9&#x02009;&#x000b1;&#x02009;4.3 y and 22.2&#x02009;&#x000b1;&#x02009;1.6&#x000a0;kg/m<sup>2</sup> in
the premenopausal women, and 25.5&#x02009;&#x000b1;&#x02009;4.3 y and
22.2&#x02009;&#x000b1;&#x02009;1.6&#x000a0;kg/m<sup>2</sup> in the men, respectively.
Indicators of compliance were the increased high-density lipoprotein (HDL)-cholesterol
and adiponectin levels after each of the three alcohol consumption periods compared with
after the alcohol-free consumption periods (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Biochemical markers of 24 young men, 24 premenopausal women, and 36
postmenopausal women sampled after an overnight fast after 4, 3 and 6-week
treatment periods, respectively, of consuming alcohol-free or
alcohol-containing beverages</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="2" align="center" valign="bottom"><bold>Young men</bold><hr/></th><th align="center" valign="bottom">&#x000a0;<hr/></th><th colspan="2" align="center" valign="bottom"><bold>Premenopausal women</bold><hr/></th><th align="center" valign="bottom">&#x000a0;<hr/></th><th colspan="2" align="center" valign="bottom"><bold>Postmenopausal women</bold><hr/></th><th align="center" valign="bottom">&#x000a0;<hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="center"><bold>Orange juice</bold></th><th align="center"><bold>Vodka and orange juice</bold></th><th align="center"><bold>
<italic>p</italic>
</bold><bold>value</bold></th><th align="center"><bold>Alcohol-free beer</bold></th><th align="center"><bold>Beer</bold></th><th align="center"><bold>
<italic>p</italic>
</bold><bold>value</bold></th><th align="center"><bold>White grape juice</bold></th><th align="center"><bold>White wine</bold></th><th align="center"><bold>
<italic>p</italic>
</bold><bold>value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Fetuin-A (&#x003bc;g/ml)<hr/></td><td align="center" valign="bottom">441&#x02009;&#x000b1;&#x02009;11<hr/></td><td align="center" valign="bottom">426&#x02009;&#x000b1;&#x02009;11<hr/></td><td align="center" valign="bottom">0.02<hr/></td><td align="center" valign="bottom">498&#x02009;&#x000b1;&#x02009;15<hr/></td><td align="center" valign="bottom">492&#x02009;&#x000b1;&#x02009;15<hr/></td><td align="center" valign="bottom">0.48<hr/></td><td align="center" valign="bottom">448&#x02009;&#x000b1;&#x02009;17<hr/></td><td align="center" valign="bottom">437&#x02009;&#x000b1;&#x02009;17<hr/></td><td align="center" valign="bottom">0.16<hr/></td></tr><tr><td align="left" valign="bottom">Adiponectin (&#x003bc;g/ml)<hr/></td><td align="center" valign="bottom">10.5&#x02009;&#x000b1;&#x02009;1.0<hr/></td><td align="center" valign="bottom">11.8&#x02009;&#x000b1;&#x02009;1.0<hr/></td><td align="center" valign="bottom">0.005<hr/></td><td align="center" valign="bottom">6.8&#x02009;&#x000b1;&#x02009;0.4<hr/></td><td align="center" valign="bottom">7.2&#x02009;&#x000b1;&#x02009;0.4<hr/></td><td align="center" valign="bottom">0.01<hr/></td><td align="center" valign="bottom">12.0&#x02009;&#x000b1;&#x02009;0.7<hr/></td><td align="center" valign="bottom">13.1&#x02009;&#x000b1;&#x02009;0.7<hr/></td><td align="center" valign="bottom">&#x0003c;0.001<hr/></td></tr><tr><td align="left" valign="bottom">Insulin (pmol/l)<hr/></td><td align="center" valign="bottom">59.8&#x02009;&#x000b1;&#x02009;8.5<hr/></td><td align="center" valign="bottom">55.7&#x02009;&#x000b1;&#x02009;8.6<hr/></td><td align="center" valign="bottom">0.53<hr/></td><td align="center" valign="bottom">45.7&#x02009;&#x000b1;&#x02009;4.0<hr/></td><td align="center" valign="bottom">46.1&#x02009;&#x000b1;&#x02009;4.0<hr/></td><td align="center" valign="bottom">0.90<hr/></td><td align="center" valign="bottom">46.5&#x02009;&#x000b1;&#x02009;3.4<hr/></td><td align="center" valign="bottom">40.0&#x02009;&#x000b1;&#x02009;3.4<hr/></td><td align="center" valign="bottom">0.90<hr/></td></tr><tr><td align="left" valign="bottom">Glucose (mmol/l)<hr/></td><td align="center" valign="bottom">5.3&#x02009;&#x000b1;&#x02009;0.10<hr/></td><td align="center" valign="bottom">5.3&#x02009;&#x000b1;&#x02009;0.10<hr/></td><td align="center" valign="bottom">0.76<hr/></td><td align="center" valign="bottom">4.8&#x02009;&#x000b1;&#x02009;0.11<hr/></td><td align="center" valign="bottom">4.8&#x02009;&#x000b1;&#x02009;0.11<hr/></td><td align="center" valign="bottom">0.36<hr/></td><td align="center" valign="bottom">5.4&#x02009;&#x000b1;&#x02009;0.11<hr/></td><td align="center" valign="bottom">5.4&#x02009;&#x000b1;&#x02009;0.11<hr/></td><td align="center" valign="bottom">0.36<hr/></td></tr><tr><td align="left" valign="bottom">HOMA-IR<hr/></td><td align="center" valign="bottom">1.98&#x02009;&#x000b1;&#x02009;0.30<hr/></td><td align="center" valign="bottom">1.87&#x02009;&#x000b1;&#x02009;0.30<hr/></td><td align="center" valign="bottom">0.61<hr/></td><td align="center" valign="bottom">1.41&#x02009;&#x000b1;&#x02009;0.11<hr/></td><td align="center" valign="bottom">1.43&#x02009;&#x000b1;&#x02009;0.11<hr/></td><td align="center" valign="bottom">0.81<hr/></td><td align="center" valign="bottom">1.64&#x02009;&#x000b1;&#x02009;0.13<hr/></td><td align="center" valign="bottom">1.42&#x02009;&#x000b1;&#x02009;0.13<hr/></td><td align="center" valign="bottom">0.02<hr/></td></tr><tr><td align="left" valign="bottom">HDL cholesterol (mmol/l)<hr/></td><td align="center" valign="bottom">1.12&#x02009;&#x000b1;&#x02009;0.05<hr/></td><td align="center" valign="bottom">1.22&#x02009;&#x000b1;&#x02009;0.05<hr/></td><td align="center" valign="bottom">0.009<hr/></td><td align="center" valign="bottom">1.52&#x02009;&#x000b1;&#x02009;0.07<hr/></td><td align="center" valign="bottom">1.62&#x02009;&#x000b1;&#x02009;0.07<hr/></td><td align="center" valign="bottom">0.008<hr/></td><td align="center" valign="bottom">1.57&#x02009;&#x000b1;&#x02009;0.07<hr/></td><td align="center" valign="bottom">1.68&#x02009;&#x000b1;&#x02009;0.07<hr/></td><td align="center" valign="bottom">&#x0003c;0.001<hr/></td></tr><tr><td align="left" valign="bottom">LDL cholesterol (mmol/l)<hr/></td><td align="center" valign="bottom">2.63&#x02009;&#x000b1;&#x02009;0.17<hr/></td><td align="center" valign="bottom">2.70&#x02009;&#x000b1;&#x02009;0.17<hr/></td><td align="center" valign="bottom">0.55<hr/></td><td align="center" valign="bottom">2.40&#x02009;&#x000b1;&#x02009;0.07<hr/></td><td align="center" valign="bottom">2.37&#x02009;&#x000b1;&#x02009;0.07<hr/></td><td align="center" valign="bottom">0.77<hr/></td><td align="center" valign="bottom">3.84&#x02009;&#x000b1;&#x02009;0.12<hr/></td><td align="center" valign="bottom">3.51&#x02009;&#x000b1;&#x02009;0.12<hr/></td><td align="center" valign="bottom">&#x0003c;0.001<hr/></td></tr><tr><td align="left" valign="bottom">Triglycerides (mmol/l)<hr/></td><td align="center" valign="bottom">1.23&#x02009;&#x000b1;&#x02009;0.14<hr/></td><td align="center" valign="bottom">1.33&#x02009;&#x000b1;&#x02009;0.14<hr/></td><td align="center" valign="bottom">0.30<hr/></td><td align="center" valign="bottom">1.27&#x02009;&#x000b1;&#x02009;0.08<hr/></td><td align="center" valign="bottom">1.25&#x02009;&#x000b1;&#x02009;0.08<hr/></td><td align="center" valign="bottom">0.61<hr/></td><td align="center" valign="bottom">1.18&#x02009;&#x000b1;&#x02009;0.08<hr/></td><td align="center" valign="bottom">1.04&#x02009;&#x000b1;&#x02009;0.08<hr/></td><td align="center" valign="bottom">&#x0003c;0.001<hr/></td></tr><tr><td align="left" valign="bottom">Free fatty acids (mmol/l)<hr/></td><td align="center" valign="bottom">0.42&#x02009;&#x000b1;&#x02009;0.03<hr/></td><td align="center" valign="bottom">0.35&#x02009;&#x000b1;&#x02009;0.03<hr/></td><td align="center" valign="bottom">0.07<hr/></td><td align="center" valign="bottom">0.34&#x02009;&#x000b1;&#x02009;0.03<hr/></td><td align="center" valign="bottom">0.29&#x02009;&#x000b1;&#x02009;0.03<hr/></td><td align="center" valign="bottom">0.26<hr/></td><td align="center" valign="bottom">0.43&#x02009;&#x000b1;&#x02009;0.04<hr/></td><td align="center" valign="bottom">0.44&#x02009;&#x000b1;&#x02009;0.04<hr/></td><td align="center" valign="bottom">0.67<hr/></td></tr><tr><td align="left" valign="bottom">Alanine aminotransferase (U/l)<hr/></td><td align="center" valign="bottom">15.2&#x02009;&#x000b1;&#x02009;1.1<hr/></td><td align="center" valign="bottom">15.9&#x02009;&#x000b1;&#x02009;1.1<hr/></td><td align="center" valign="bottom">0.49<hr/></td><td align="center" valign="bottom">10.8&#x02009;&#x000b1;&#x02009;1.8<hr/></td><td align="center" valign="bottom">10.0&#x02009;&#x000b1;&#x02009;1.8<hr/></td><td align="center" valign="bottom">0.21<hr/></td><td align="center" valign="bottom">13.8&#x02009;&#x000b1;&#x02009;2.5<hr/></td><td align="center" valign="bottom">17.4&#x02009;&#x000b1;&#x02009;2.5<hr/></td><td align="center" valign="bottom">0.29<hr/></td></tr><tr><td align="left" valign="bottom">Alkaline phosphates (U/l)<hr/></td><td align="center" valign="bottom">65.1&#x02009;&#x000b1;&#x02009;4.3<hr/></td><td align="center" valign="bottom">65.8&#x02009;&#x000b1;&#x02009;4.3<hr/></td><td align="center" valign="bottom">0.70<hr/></td><td align="center" valign="bottom">56.9&#x02009;&#x000b1;&#x02009;6.5<hr/></td><td align="center" valign="bottom">57.8&#x02009;&#x000b1;&#x02009;6.5<hr/></td><td align="center" valign="bottom">0.68<hr/></td><td align="center" valign="bottom">72.7&#x02009;&#x000b1;&#x02009;2.9<hr/></td><td align="center" valign="bottom">73.6&#x02009;&#x000b1;&#x02009;2.9<hr/></td><td align="center" valign="bottom">0.73<hr/></td></tr><tr><td align="left" valign="bottom">Aspartate aminotransferase (U/l)<hr/></td><td align="center" valign="bottom">21.0&#x02009;&#x000b1;&#x02009;1.0<hr/></td><td align="center" valign="bottom">20.6&#x02009;&#x000b1;&#x02009;1.0<hr/></td><td align="center" valign="bottom">0.62<hr/></td><td align="center" valign="bottom">17.8&#x02009;&#x000b1;&#x02009;2.0<hr/></td><td align="center" valign="bottom">17.8&#x02009;&#x000b1;&#x02009;2.0<hr/></td><td align="center" valign="bottom">0.95<hr/></td><td align="center" valign="bottom">20.9&#x02009;&#x000b1;&#x02009;2.0<hr/></td><td align="center" valign="bottom">24.8&#x02009;&#x000b1;&#x02009;2.0<hr/></td><td align="center" valign="bottom">0.13<hr/></td></tr><tr><td align="left">&#x003b3;-Glutamyltransferase (U/l)</td><td align="center">19.8&#x02009;&#x000b1;&#x02009;2.4</td><td align="center">24.3&#x02009;&#x000b1;&#x02009;2.4</td><td align="center">0.003</td><td align="center">16.5&#x02009;&#x000b1;&#x02009;2.2</td><td align="center">18.5&#x02009;&#x000b1;&#x02009;2.2</td><td align="center">0.01</td><td align="center">18.4&#x02009;&#x000b1;&#x02009;5.2</td><td align="center">27.5&#x02009;&#x000b1;&#x02009;5.2</td><td align="center">0.21</td></tr></tbody></table><table-wrap-foot><p>Data are presented as means&#x02009;&#x000b1;&#x02009;SEM. <italic>P</italic> values are
obtained from a mixed-model ANOVA. Abbreviations: HOMA-IR homeostasis model
assessment of insulin resistance; HDL high-density lipoprotein; LDL low-density
lipoprotein.</p></table-wrap-foot></table-wrap><p>No carry-over effects were found in fetuin-A, indicating that a possible effect on
fetuin-A levels due to a treatment given in the first time period of the crossover trial
did not persist into the second period and influence the effect of the second treatment.
Fetuin-A levels decreased in men after vodka juice consumption
(441&#x02009;&#x000b1;&#x02009;11 to 426&#x02009;&#x000b1;&#x02009;11&#x000a0;&#x003bc;g/ml,
<italic>p</italic>&#x02009;=&#x02009;0.02) but not significantly in postmenopausal women after wine
(448&#x02009;&#x000b1;&#x02009;17 to 437&#x02009;&#x000b1;&#x02009;17&#x000a0;&#x003bc;g/ml,
<italic>p</italic>&#x02009;=&#x02009;0.16) or in premenopausal women after beer consumption
(498&#x02009;&#x000b1;&#x02009;15 to 492&#x02009;&#x000b1;&#x02009;15&#x000a0;&#x003bc;g/ml,
<italic>p</italic>&#x02009;=&#x02009;0.48) (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>) as compared to
levels after each corresponding alcohol-free beverage consumption.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Individual changes of circulating fetuin-A levels at the end of the alcohol or
alcohol-free treatment periods after an overnight fast for three open-label
randomized crossover trials.</p></caption><graphic xlink:href="1758-5996-6-24-1"/></fig><p>No correlations were observed between alcohol-induced changes in fetuin-A and
corresponding changes in the homeostasis model assessment of insulin resistance
(HOMA-IR) (&#x003c1;&#x02009;=&#x02009;0.01, <italic>p</italic>&#x02009;=&#x02009;0.95;
&#x003c1;&#x02009;=&#x02009;0.25, <italic>p</italic>&#x02009;=&#x02009;0.26; &#x003c1;&#x02009;=&#x02009;0.20,
<italic>p</italic>&#x02009;=&#x02009;0.24) or changes in adiponectin (&#x003c1;&#x02009;=&#x02009;0.22,
<italic>p</italic>&#x02009;=&#x02009;0.31; &#x003c1;&#x02009;=&#x02009;0.17,
<italic>p</italic>&#x02009;=&#x02009;0.44; &#x003c1;&#x02009;=&#x02009;0.25, <italic>p</italic>&#x02009;=&#x02009;0.15)
among young men, pre- or postmenopausal women, respectively. Changes in HOMA-IR and
adiponectin were also not correlated among men (&#x003c1;&#x02009;=&#x02009;0.14,
<italic>p</italic>&#x02009;=&#x02009;0.51), premenopausal women (&#x003c1;&#x02009;=&#x02009;0.01,
<italic>p</italic>&#x02009;=&#x02009;0.96), or postmenopausal women (&#x003c1;&#x02009;=&#x02009;0.27,
<italic>p</italic>&#x02009;=&#x02009;0.11). Also, no consistent correlations were observed
between alcohol-induced changes in fetuin-A and analogous changes in fasting blood
lipids including HDL-cholesterol and free fatty acids (FFA), or liver function
parameters across the three trials.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In post-hoc analyses of three separate open-label randomized crossover intervention
studies, we found that moderate alcohol consumption reduced fetuin-A levels in men but
not in women. This decrease was apparent after four weeks of moderate vodka consumption.
No consistent correlations between intervention-induced changes in fetuin-A and other
biochemical markers were observed across the three studies.</p><p>To our knowledge, these are the first intervention studies investigating the effect of
different alcohol-containing beverages on circulating fetuin-A. The lowered fetuin-A
levels in men after moderate alcohol consumption partially confirm cross-sectional
observations in several epidemiological studies [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>] and may provide some physiological support for the protective effect of
moderate alcohol consumption on the risk of developing type 2 diabetes [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B8">8</xref>] besides adiponectin [<xref ref-type="bibr" rid="B15">15</xref>]. Furthermore, these findings extend prior evidence of short-term clinical
trials that noted favourable changes in selected biological markers associated with
diabetes and cardiovascular risk after moderate alcohol consumption [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>The underlying physiological explanation how alcohol consumption may lower fetuin-A is
not clear. Also, the sex-specific alcohol-fetuin-A effect was unexpected, particularly
since all women were either on oral contraceptives or postmenopausal, which limits
potential influences of hormonal fluctuations or menstrual cycles. The null finding in
our trials among pre- and postmenopausal women do not seem to correspond with a previous
observational study among 1331 middle-aged and older US female nurses, where moderate
alcohol consumption was inversely associated with plasma fetuin-A even after adjustment
for several lifestyle variables, demographic information, and medical history [<xref ref-type="bibr" rid="B6">6</xref>]. Perhaps this discrepancy can be explained by the low statistical power in
the two trials among women. Post-hoc power analyses indicated that the power to detect a
similar effect as observed in men was only 30% among the postmenopausal women and 31%
among the premenopausal women.</p><p>Circulating fetuin-A was strongly and negatively associated with the insulin-sensitizing
adipokine adiponectin in humans [<xref ref-type="bibr" rid="B17">17</xref>] and treatment of human adipocytes with fetuin-A repressed <italic>ADIPOQ</italic>
mRNA levels [<xref ref-type="bibr" rid="B17">17</xref>]. Furthermore, given the prior associations between fetuin-A and insulin
resistance [<xref ref-type="bibr" rid="B18">18</xref>] and insulin sensitivity [<xref ref-type="bibr" rid="B19">19</xref>], we hypothesized that reductions in fetuin-A may play a role in the increased
adiponectin levels or improved insulin sensitivity after alcohol consumption [<xref ref-type="bibr" rid="B10">10</xref>]. Therefore, we analyzed correlations between intervention-induced changes in
fetuin-A and adiponectin levels and other markers of insulin sensitivity, such as
HOMA-IR. We, however, did not find such inverse correlations despite the fact that
moderate alcohol consumption increased both <italic>ADIPOQ</italic> expression [<xref ref-type="bibr" rid="B10">10</xref>] and corresponding circulating adiponectin levels [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>], suggesting that fetuin-A and adiponectin levels may be independently
affected by alcohol. Also, it is important to note that the HOMA-IR index is a weak
estimate of insulin resistance, particularly in a small study. The absence of a
correlation between alcohol-induced changes in fetuin-A and HOMA-IR may partially be
explained by the relatively low FFA levels of the studied participants. In a study among
347 healthy subjects at increased risk of type 2 diabetes, fetuin-A was only inversely
associated with insulin sensitivity among individuals with high FFA levels
(~&#x02009;&#x0003e;&#x02009;0.65&#x000a0;mmol/l) [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Strengths of the study are the randomized crossover design (considered the &#x02018;gold
standard&#x02019; for evidence-based research), the assessment of compliance markers (i.e.
HDL-cholesterol and adiponectin) to the study treatments, the inclusion of both sexes,
and the broad range of biochemical variables. Some limitations warrant consideration.
The trials consisted of alcohol-administration periods of 3 to 6&#x000a0;weeks and were
performed among fairly insulin-sensitive subjects. Maybe more profound effects on
fetuin-A levels would have been observed if the interventions lasted longer and/or were
executed in subjects with glucose levels in the (pre)diabetic range. For example, three
months of moderate alcohol consumption decreased fasting glucose levels among subjects
with impaired glucose metabolism [<xref ref-type="bibr" rid="B21">21</xref>] and fetuin-A levels were particularly associated with an increased diabetes
risk among subjects with higher fasting glucose [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Regardless, the duration of the present interventions were long enough to
detect alcohol-induced changes in other biochemical markers such as adiponectin and
HDL-cholesterol. Also, the association between moderate alcohol consumption and lower
risk of type 2 diabetes mellitus is not limited to subjects with impaired glucose
metabolism but also exists for subjects already at low risk for diabetes on the basis of
multiple combined low-risk lifestyle behaviours [<xref ref-type="bibr" rid="B22">22</xref>]. Nevertheless, the subjects studied were rather lean (mean BMI values 22-26),
had no fatty liver (low liver enzyme levels) and were rather insulin sensitive (low
HOMA-IR). Also, all premenopausal women used oestrogen-containing oral contraceptives,
which may explain their somewhat higher fetuin-A levels given the positive associations
between oestrogen and fetuin-A [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. Thus, the data are not representative for a typical at-risk population for
metabolic diseases. Second, the daily amounts of alcohol consumed by women (~25&#x000a0;g
alcohol) were higher than what is considered &#x02018;moderate&#x02019; according to most
guidelines (i.e. max. ~15&#x000a0;g alcohol). However, the nadir of the alcohol-diabetes
association for women appeared to be at 24&#x000a0;g of alcohol/day in a meta-analysis of
20 prospective studies [<xref ref-type="bibr" rid="B8">8</xref>] while alcohol consumption became harmful above 50&#x000a0;g/day (and above
60&#x000a0;g/day for men). Third, post-hoc power analyses showed that there was low
statistical power in the two trials among women to detect a similar effect as observed
in the trial among men. Fourth, although unlikely since vodka is basically an
ethanol-water mixture, we cannot fully exclude a potential beverage-specific effect.
Finally, the alcohol-induced reductions in fetuin-A were comparable to associations
reported in epidemiological studies [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>], but were relatively small as compared to alcohol&#x02019;s effect on
HDL-cholesterol and adiponectin. It is possible that the findings, including the sex
differences, were due to chance.</p><p>In conclusion, the results of these three randomized clinical trials with different
alcohol-containing beverages demonstrated that short-term moderate alcohol consumption
decreases fetuin-A levels in men but not in women. Further research is needed to
determine whether long-term moderate alcohol consumption decreases fetuin-A levels. If
so, these findings may add to the current knowledge of possible metabolic benefits of
moderate alcohol consumption.</p></sec><sec><title>Abbreviations</title><p>ANOVA: Analysis of variation; BMI: Body mass index; ELISA: Enzyme-linked immunosorbent
assay; FFA: Free fatty acids; HDL-cholesterol: High-density lipoprotein-cholesterol;
HOMA-IR: Homeostasis model assessment of insulin resistance; SEM: Standard error of the
mean.</p></sec><sec><title>Competing interests</title><p>The authors have no potential conflicts relevant to this article.</p></sec><sec><title>Authors&#x02019; contributions</title><p>MMJ conceived the idea of the study, designed the study, directed the study&#x02019;s
implementation, conducted the statistical analyses, interpreted the data, and wrote the
manuscript. ICS assisted in the study&#x02019;s implementation, assisted in the
interpretation of the data, and critically edited the manuscript. HFJH designed the
study, directed the study&#x02019;s implementation, assisted in the interpretation of the
data, critically edited the manuscript, and obtained funding. All authors read and
approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>This work was supported by the Dutch Ministry of Economic Affairs, Agriculture and
Innovation and by the Dutch Foundation for Alcohol Research (SAR) representing Dutch
producers of and traders in beer, wine and spirits and by TNO. Their joint aim is to
independently study the health effects of moderate alcohol consumption.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Goustin</surname><given-names>AS</given-names></name><name><surname>Abou-Samra</surname><given-names>AB</given-names></name><article-title>The "thrifty" gene encoding Ahsg/Fetuin-A meets the insulin receptor: insights
into the mechanism of insulin resistance</article-title><source>Cell Signal</source><year>2011</year><volume>23</volume><fpage>980</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2010.11.003</pub-id><pub-id pub-id-type="pmid">21087662</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>Haring</surname><given-names>HU</given-names></name><article-title>The role of hepatokines in metabolism</article-title><source>Nat Rev Endocrinol</source><year>2013</year><volume>9</volume><fpage>144</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2012.258</pub-id><pub-id pub-id-type="pmid">23337953</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>Fritsche</surname><given-names>A</given-names></name><name><surname>Weikert</surname><given-names>C</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Joost</surname><given-names>HG</given-names></name><name><surname>Haring</surname><given-names>HU</given-names></name><name><surname>Schulze</surname><given-names>MB</given-names></name><article-title>Plasma fetuin-A levels and the risk of type 2 diabetes</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>2762</fpage><lpage>2767</lpage><pub-id pub-id-type="doi">10.2337/db08-0538</pub-id><pub-id pub-id-type="pmid">18633113</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Ix</surname><given-names>JH</given-names></name><name><surname>Biggs</surname><given-names>ML</given-names></name><name><surname>Mukamal</surname><given-names>KJ</given-names></name><name><surname>Kizer</surname><given-names>JR</given-names></name><name><surname>Zieman</surname><given-names>SJ</given-names></name><name><surname>Siscovick</surname><given-names>DS</given-names></name><name><surname>Mozzaffarian</surname><given-names>D</given-names></name><name><surname>Jensen</surname><given-names>MK</given-names></name><name><surname>Nelson</surname><given-names>L</given-names></name><name><surname>Ruderman</surname><given-names>N</given-names></name><name><surname>Djousse</surname><given-names>L</given-names></name><article-title>Association of fetuin-A with incident diabetes mellitus in community-living older
adults: the cardiovascular health study</article-title><source>Circulation</source><year>2012</year><volume>125</volume><fpage>2316</fpage><lpage>2322</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.072751</pub-id><pub-id pub-id-type="pmid">22511752</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Laughlin</surname><given-names>GA</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Cummins</surname><given-names>KM</given-names></name><name><surname>Daniels</surname><given-names>LB</given-names></name><name><surname>Wassel</surname><given-names>CL</given-names></name><name><surname>Ix</surname><given-names>JH</given-names></name><article-title>Sex-specific association of fetuin-A with type 2 diabetes in older
community-dwelling adults: the Rancho Bernardo study</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>1994</fpage><lpage>2000</lpage><pub-id pub-id-type="doi">10.2337/dc12-1870</pub-id><pub-id pub-id-type="pmid">23315604</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Ley</surname><given-names>SH</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Jimenez</surname><given-names>MC</given-names></name><name><surname>Rexrode</surname><given-names>KM</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Jensen</surname><given-names>MK</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><article-title>Association between alcohol consumption and plasma fetuin-A and its contribution
to incident type 2 diabetes in women</article-title><source>Diabetologia</source><year>2014</year><volume>57</volume><fpage>93</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1007/s00125-013-3077-8</pub-id><pub-id pub-id-type="pmid">24105100</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Koppes</surname><given-names>LL</given-names></name><name><surname>Dekker</surname><given-names>JM</given-names></name><name><surname>Hendriks</surname><given-names>HF</given-names></name><name><surname>Bouter</surname><given-names>LM</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name><article-title>Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis
of prospective observational studies</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>719</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.2337/diacare.28.3.719</pub-id><pub-id pub-id-type="pmid">15735217</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Baliunas</surname><given-names>DO</given-names></name><name><surname>Taylor</surname><given-names>BJ</given-names></name><name><surname>Irving</surname><given-names>H</given-names></name><name><surname>Roerecke</surname><given-names>M</given-names></name><name><surname>Patra</surname><given-names>J</given-names></name><name><surname>Mohapatra</surname><given-names>S</given-names></name><name><surname>Rehm</surname><given-names>J</given-names></name><article-title>Alcohol as a risk factor for type 2 diabetes: a systematic review and
meta-analysis</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>2123</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.2337/dc09-0227</pub-id><pub-id pub-id-type="pmid">19875607</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Joosten</surname><given-names>MM</given-names></name><name><surname>Chiuve</surname><given-names>SE</given-names></name><name><surname>Mukamal</surname><given-names>KJ</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Hendriks</surname><given-names>HF</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><article-title>Changes in alcohol consumption and subsequent risk of type 2 diabetes in men</article-title><source>Diabetes</source><year>2011</year><volume>60</volume><fpage>74</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.2337/db10-1052</pub-id><pub-id pub-id-type="pmid">20876712</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Joosten</surname><given-names>MM</given-names></name><name><surname>Beulens</surname><given-names>JW</given-names></name><name><surname>Kersten</surname><given-names>S</given-names></name><name><surname>Hendriks</surname><given-names>HF</given-names></name><article-title>Moderate alcohol consumption increases insulin sensitivity and ADIPOQ expression
in postmenopausal women: a randomised, crossover trial</article-title><source>Diabetologia</source><year>2008</year><volume>51</volume><fpage>1375</fpage><lpage>1381</lpage><pub-id pub-id-type="doi">10.1007/s00125-008-1031-y</pub-id><pub-id pub-id-type="pmid">18504547</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Joosten</surname><given-names>MM</given-names></name><name><surname>Witkamp</surname><given-names>RF</given-names></name><name><surname>Hendriks</surname><given-names>HF</given-names></name><article-title>Alterations in total and high-molecular-weight adiponectin after 3&#x000a0;weeks of
moderate alcohol consumption in premenopausal women</article-title><source>Metabolism</source><year>2011</year><volume>60</volume><fpage>1058</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2011.01.001</pub-id><pub-id pub-id-type="pmid">21353262</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Joosten</surname><given-names>MM</given-names></name><name><surname>van Erk</surname><given-names>MJ</given-names></name><name><surname>Pellis</surname><given-names>L</given-names></name><name><surname>Witkamp</surname><given-names>RF</given-names></name><name><surname>Hendriks</surname><given-names>HF</given-names></name><article-title>Moderate alcohol consumption alters both leucocyte gene expression profiles and
circulating proteins related to immune response and lipid metabolism in men</article-title><source>Br J Nutr</source><year>2012</year><volume>108</volume><fpage>620</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1017/S0007114511005988</pub-id><pub-id pub-id-type="pmid">22142458</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Weikert</surname><given-names>C</given-names></name><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>Schulze</surname><given-names>MB</given-names></name><name><surname>Pischon</surname><given-names>T</given-names></name><name><surname>Berger</surname><given-names>K</given-names></name><name><surname>Joost</surname><given-names>HG</given-names></name><name><surname>Haring</surname><given-names>HU</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Fritsche</surname><given-names>A</given-names></name><article-title>Plasma fetuin-A levels and the risk of myocardial infarction and ischemic
stroke</article-title><source>Circulation</source><year>2008</year><volume>118</volume><fpage>2555</fpage><lpage>2562</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.814418</pub-id><pub-id pub-id-type="pmid">19029462</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Jensen</surname><given-names>MK</given-names></name><name><surname>Bartz</surname><given-names>TM</given-names></name><name><surname>Mukamal</surname><given-names>KJ</given-names></name><name><surname>Djousse</surname><given-names>L</given-names></name><name><surname>Kizer</surname><given-names>JR</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Zieman</surname><given-names>SJ</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><name><surname>Siscovick</surname><given-names>DS</given-names></name><name><surname>Shlipak</surname><given-names>M</given-names></name><name><surname>Ix</surname><given-names>JH</given-names></name><article-title>Fetuin-A, type 2 diabetes, and risk of cardiovascular disease in older adults: the
cardiovascular health study</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>1222</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.2337/dc12-1591</pub-id><pub-id pub-id-type="pmid">23250801</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Beulens</surname><given-names>JW</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Hendriks</surname><given-names>HF</given-names></name><name><surname>Mukamal</surname><given-names>KJ</given-names></name><article-title>Alcohol consumption, mediating biomarkers, and risk of type 2 diabetes among
middle-aged women</article-title><source>Diabetes Care</source><year>2008</year><volume>31</volume><fpage>2050</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.2337/dc08-0814</pub-id><pub-id pub-id-type="pmid">18628567</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Brien</surname><given-names>SE</given-names></name><name><surname>Ronksley</surname><given-names>PE</given-names></name><name><surname>Turner</surname><given-names>BJ</given-names></name><name><surname>Mukamal</surname><given-names>KJ</given-names></name><name><surname>Ghali</surname><given-names>WA</given-names></name><article-title>Effect of alcohol consumption on biological markers associated with risk of
coronary heart disease: systematic review and meta-analysis of interventional
studies</article-title><source>BMJ</source><year>2011</year><volume>342</volume><fpage>d636</fpage><pub-id pub-id-type="doi">10.1136/bmj.d636</pub-id><pub-id pub-id-type="pmid">21343206</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Hennige</surname><given-names>AM</given-names></name><name><surname>Staiger</surname><given-names>H</given-names></name><name><surname>Wicke</surname><given-names>C</given-names></name><name><surname>Machicao</surname><given-names>F</given-names></name><name><surname>Fritsche</surname><given-names>A</given-names></name><name><surname>Haring</surname><given-names>HU</given-names></name><name><surname>Stefan</surname><given-names>N</given-names></name><article-title>Fetuin-A induces cytokine expression and suppresses adiponectin production</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><fpage>e1765</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0001765</pub-id><pub-id pub-id-type="pmid">18335040</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>Hennige</surname><given-names>AM</given-names></name><name><surname>Staiger</surname><given-names>H</given-names></name><name><surname>Machann</surname><given-names>J</given-names></name><name><surname>Schick</surname><given-names>F</given-names></name><name><surname>Krober</surname><given-names>SM</given-names></name><name><surname>Machicao</surname><given-names>F</given-names></name><name><surname>Fritsche</surname><given-names>A</given-names></name><name><surname>Haring</surname><given-names>HU</given-names></name><article-title>Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance
and fat accumulation in the liver in humans</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>853</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.2337/diacare.29.04.06.dc05-1938</pub-id><pub-id pub-id-type="pmid">16567827</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Emoto</surname><given-names>M</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Araki</surname><given-names>T</given-names></name><name><surname>Teramura</surname><given-names>M</given-names></name><name><surname>Koyama</surname><given-names>H</given-names></name><name><surname>Shoji</surname><given-names>T</given-names></name><name><surname>Inaba</surname><given-names>M</given-names></name><name><surname>Nishizawa</surname><given-names>Y</given-names></name><article-title>Association of serum fetuin-A with insulin resistance in type 2 diabetic and
nondiabetic subjects</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>468</fpage><pub-id pub-id-type="doi">10.2337/diacare.29.02.06.dc05-1484</pub-id><pub-id pub-id-type="pmid">16443916</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>Haring</surname><given-names>HU</given-names></name><article-title>Circulating fetuin-A and free fatty acids interact to predict insulin resistance
in humans</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><fpage>394</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1038/nm.3116</pub-id><pub-id pub-id-type="pmid">23558619</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Shai</surname><given-names>I</given-names></name><name><surname>Wainstein</surname><given-names>J</given-names></name><name><surname>Harman-Boehm</surname><given-names>I</given-names></name><name><surname>Raz</surname><given-names>I</given-names></name><name><surname>Fraser</surname><given-names>D</given-names></name><name><surname>Rudich</surname><given-names>A</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><article-title>Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: a
multicenter, randomized, clinical intervention trial</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>3011</fpage><lpage>3016</lpage><pub-id pub-id-type="doi">10.2337/dc07-1103</pub-id><pub-id pub-id-type="pmid">17848609</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Joosten</surname><given-names>MM</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>van der</surname><given-names>AD</given-names></name><name><surname>Verschuren</surname><given-names>WM</given-names></name><name><surname>Hendriks</surname><given-names>HF</given-names></name><name><surname>Beulens</surname><given-names>JW</given-names></name><article-title>Combined effect of alcohol consumption and lifestyle behaviors on risk of type 2
diabetes</article-title><source>Am J Clin Nutr</source><year>2010</year><volume>91</volume><fpage>1777</fpage><lpage>1783</lpage><pub-id pub-id-type="doi">10.3945/ajcn.2010.29170</pub-id><pub-id pub-id-type="pmid">20410096</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Laughlin</surname><given-names>GA</given-names></name><name><surname>Cummins</surname><given-names>KM</given-names></name><name><surname>Wassel</surname><given-names>CL</given-names></name><name><surname>Daniels</surname><given-names>LB</given-names></name><name><surname>Ix</surname><given-names>JH</given-names></name><article-title>The association of fetuin-A with cardiovascular disease mortality in older
community-dwelling adults: the Rancho Bernardo study</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>59</volume><fpage>1688</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2012.01.038</pub-id><pub-id pub-id-type="pmid">22554599</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Rasul</surname><given-names>S</given-names></name><name><surname>Ilhan</surname><given-names>A</given-names></name><name><surname>Reiter</surname><given-names>MH</given-names></name><name><surname>Todoric</surname><given-names>J</given-names></name><name><surname>Farhan</surname><given-names>S</given-names></name><name><surname>Esterbauer</surname><given-names>H</given-names></name><name><surname>Kautzky-Willer</surname><given-names>A</given-names></name><article-title>Levels of fetuin-A relate to the levels of bone turnover biomarkers in male and
female patients with type 2 diabetes</article-title><source>Clin Endocrinol (Oxf)</source><year>2012</year><volume>76</volume><fpage>499</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2265.2011.04246.x</pub-id><pub-id pub-id-type="pmid">21958193</pub-id></mixed-citation></ref></ref-list></back></article>